id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263419-qeo6qn0d	Fiorino, Gionata	Protecting patients with IBD during the COVID-19 pandemic	2020-05-20		.txt	text/plain	417	31	44	An and colleagues stopped biologics (infliximab infusions) and immunosuppressive treatments for all patients with IBD. Indeed, a systematic review 4 showed that the risk of hospital admission (odds ratio 0·48, 95% CI 0·29-0·80) and surgery (0·67, 0·46-0·97) is significantly reduced by use of biologics for patients with IBD. The probability of relapse after stopping effective immunomodulators or biological therapy is about 50% and is associated with an increased need for steroids, and risk of hospital admission and surgery. Thus, the risk and benefits of continuing or stopping biologics should be carefully balanced and should not be assumed to be a general rule for all patients with IBD, especially given the length of time the pandemic is likely to last. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease	./cache/cord-263419-qeo6qn0d.txt	./txt/cord-263419-qeo6qn0d.txt